文献速递慢性肾脏病

经皮检测法测定肾小球滤过率

GFR Measurement Using Transdermal Detection Methodology.
PubMed 文献 · J Am Soc Nephrol · 2025-02-07

多中心研究纳入74例eGFR正常至CKD 4期的参与者,经皮检测荧光示踪剂relmapirazin的荧光衰减,用两室药代动力学模型推算荧光清除率,并与血浆法测得的GFR进行线性回归比较,r²为0.90,P30为91.9%。

要点

  • 经皮荧光检测relmapirazin可在护理点测定GFR,覆盖临床有意义的GFR范围和全部肤色类型。
  • 经皮推导的GFR与血浆推导的GFR线性回归r²为0.90(95%CI 0.85–0.94),P30为91.9%。
  • 研究未报告严重不良事件,支持该方法的可行性。

核心结论

  • 经皮检测荧光示踪剂relmapirazin在肾功能正常至受损患者及不同肤色类型中可行。

研究设计与样本

  • 参与者静脉推注relmapirazin 1.5 mg/kg,经皮采集荧光12小时,用两室药代动力学模型提取荧光清除率。
  • 同期测定血浆relmapirazin浓度并确定血浆GFR,用线性回归比较荧光清除率与索引血浆GFR。

主要发现

  • 参与者年龄范围23–80岁,女性占59%。
  • 荧光强度-时间数据呈两室药代动力学行为,所有完成12小时研究的参与者均成功推导出荧光清除率。
  • 荧光清除率与索引血浆GFR的线性回归r²为0.90(95%CI 0.85–0.94),覆盖所测GFR范围和所有肤色。
  • 未报告严重不良事件。

临床怎么用

  • 该经皮检测方法有望在护理点测定GFR,覆盖临床有意义的GFR范围和不同肤色人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Transdermal fluorescence detection of GFR measurement at the point of care with the fluorescent GFR tracer agent relmapirazin was evaluated. Measurement over the entire range of clinically meaningful GFR and the entire range of human skin tones was demonstrated. A linear regression of transdermally derived GFR to plasma-derived GFR yielded an r2 of 0.90 and P30 of 91.9%. BACKGROUND: The well-known accuracy limitations of eGFR currently used in clinical practice present barriers to optimal care for patients with, or at risk of, decreased kidney function. A point-of-care GFR measurement methodology has the potential to address these limitations. We prospectively assessed transdermal detection of the novel fluorescent GFR tracer agent relmapirazin in participants having normal or impaired kidney function across all human skin colors on the Fitzpatrick Skin Scale (FSS). METHODS: A multicenter study comprising 74 participants with eGFR from normal to stage 4 CKD was performed. Forty-six participants were FSS types 1–3, and 28 were FSS types 4–6. A module containing a light-emitting diode and photodetector to activate and collect transdermal relmapirazin fluorescence was attached adhesively to the upper chest of each participant. Relmapirazin (1.5 mg/kg) was administered by intravenous push, and fluorescence emission was acquired for 12 hours. A two-compartment pharmacokinetic model fit the fluorescent intensity versus time data, and fluorescence clearance rate (FCR) was extracted from the second (terminal) compartment. Plasma relmapirazin concentrations were measured contemporaneously, and the corresponding plasma GFR for each participant was determined. Linear regression analysis was used to compare the FCR with the indexed plasma GFR. RESULTS: Participant age range was 23–80 years, with 59% female. The two-compartment pharmacokinetic behavior was observed in the fluorescence intensity versus time data, and a FCR was successfully deduced for every participant completing the 12-hour study. The FCR versus indexed plasma GFR yielded an excellent correlation over the range of GFR measured and for all skin colors with a r2 of 0.90 (95% confidence interval, 0.85 to 0.94). No severe adverse events were reported. CONCLUSIONS: Point-of-care transdermal detection of the fluorescent GFR tracer agent relmapirazin was feasible in patients with normal to impaired kidney function and for a range of skin color types. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:: ClinicalTrials.gov, NCT02772276.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Dorshow RB, Debreczeny MP, Goldstein SL, et al. GFR Measurement Using Transdermal Detection Methodology. J Am Soc Nephrol. 2025. PMID: 39918882. doi:10.1681/ASN.0000000639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。